



Contents lists available at ScienceDirect

Parkinsonism and Related Disorders

journal homepage: www.elsevier.com/locate/parkreldis

Short communication

Parkinsonian axial signs in schizophrenia

Francesca Morgante^{a, b, *}, Corrado Barbui^{b, c}, Michele Tinazzi^{c, d}, on behalf of the Italian DIP study group¹^a Dipartimento di Medicina Clinica e Sperimentale, University of Messina, Italy^b Institute of Molecular and Clinical Sciences, St George's University of London, London, United Kingdom^c WHO Collaborating Centre for Research and Training in Mental Health and Service Evaluation, Department of Neuroscience, Biomedicine and Motor Sciences, Section of Psychiatry, University of Verona, Italy^d Department of Neuroscience, Biomedicine and Motor Sciences, University of Verona, Italy

ARTICLE INFO

Article history:

Received 20 October 2016

Received in revised form

15 December 2016

Accepted 21 December 2016

Keywords:

Schizophrenia

Parkinson's disease

Antipsychotic drugs

Axial parkinsonian signs

List of abbreviations:

APs

antipsychotic drugs

DDD

defined daily dose

DIP

Drug-induced parkinsonism

DRBA

dopamine receptor blocking agents

123I-FP-CIT SPECT

single photon emission computed

tomography of dopamine transporter

PD

Parkinson's disease

PDD

prescribed daily dose

Schiz- Axial

schizophrenia with axial parkinsonian signs

Schiz-NO-Axial

schizophrenia without axial parkinsonian

signs

UPDRS

Unified Parkinson's Disease Rating Scale

A B S T R A C T

Introduction: We have recently demonstrated evidence of nigro-striatal denervation, disease progression and response to levodopa in a subgroup of patients with schizophrenia who developed parkinsonism.**Objective:** In the present study, we investigated whether axial parkinsonian signs might be an early manifestation of parkinsonism in schizophrenia not necessarily related to chronic administration of antipsychotic drugs (AP) drugs.**Methods:** From a baseline cohort of 299 schizophrenic patients who did not satisfy the diagnostic criteria for parkinsonism (presence of at least two of the following appendicular signs: bradykinesia, tremor, rigidity), we identified a group of patients who manifested two out of three axial parkinsonian signs (abnormality of trunk posture, hypomimia and short-step gait). Accordingly, we obtained two sub-groups of patients with schizophrenia, with (*Schiz-Axial*, N = 26), and without parkinsonian axial signs (*Schiz-NO-Axial*, N = 273). Clinical and demographical variables were compared between groups. The motor section of the Unified Parkinson's disease rating scale (UPDRS) was employed to measure motor disability.**Results:** *Schiz-Axial* patients were significantly older ($p = 0.007$) and had longer disease duration ($p = 0.04$) compared to *Schiz-NO-Axial*. The two groups did not differ for variables related to AP treatment. Total UPDRS motor score ($p < 0.0001$) as well as limb ($p < 0.0001$) and axial ($p < 0.0001$) UPDRS sub-scores were increased in *Schiz-Axial* patients compared to *Schiz-NO-Axial*.**Conclusions:** Our findings provide evidence that axial parkinsonian signs might be an early manifestation of parkinsonism in schizophrenia associated to older age and longer disease duration.

© 2016 Elsevier Ltd. All rights reserved.

* Corresponding author. UOSD Disordini del Movimento, AOU G. Martino, Università di Messina Via Consolare Valeria 1, pad. E, 2° piano, 98125 Messina, Italy.

E-mail address: fmorgante@gmail.com (F. Morgante).¹ Italian DIP study group: Antonino Cannas, Department of Cardiovascular and Neurological Sciences, Section of Neurology, University of Cagliari, Italy; Mario Zappia, Department "GF Ingrassia", Section of Neurosciences, University of Catania; Letterio Morgante, Department of Neuroscience, University of Messina; Claudio Pacchetti, Parkinson's Disease and Movement Disorders Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) C. Mondino National Institute of Neurology Foundation, Pavia; Carlo Dallochio, Division of Neurology, The Civil Hospital, Voghera; Simone Rossi, Department of Neurosciences, Section of Neurology, University of Siena; Roberto Ceravolo, Department of Clinical and Experimental Medicine, University of Pisa.

1. Introduction

Patients with schizophrenia may develop parkinsonism, likely as result of chronic administration of antipsychotic (AP) drugs. Nevertheless, we have recently suggested that parkinsonism associated to schizophrenia recognizes a multifactorial pathogenesis, not being entirely due to post-synaptic D2-receptors blockade by dopamine receptor blocking agents (DRBA) [1,2]. Indeed, a subgroup of patients with schizophrenia, exhibit abnormalities of single photon emission computed tomography of dopamine transporter (^{123}I -FP-CIT SPECT) [2], progression of motor disability over 2-years follow-up and response to levodopa [1]; these findings are in line with the hypothesis that neurodegenerative changes in the nigro-striatal pathway may occur in schizophrenia and may be partly responsible of parkinsonian signs [3]. Using unpublished data from our previous cross-sectional study that investigated parkinsonism in patients with schizophrenia, we identified subjects who did not satisfy the criteria for parkinsonism diagnosis, but who manifested two out of three parkinsonian axial signs among gait impairment, hypomimia, trunk postural abnormalities. In this cohort of patients, we investigated whether axial parkinsonian signs might represent an early manifestation of parkinsonism in schizophrenia not necessarily related to chronic administration of AP drugs.

2. Methods

An extensive description of the enrollment methodology is described elsewhere [2]. Briefly, outpatients fulfilling DSM-IV criteria for schizophrenia were consecutively enrolled by trained psychiatrists in eight recruiting centers. Patients were only included in the study if they gave written, informed consent to participate. All study sites gained full approval for the study from the local research Ethics Committee. Patients were informed by the treating psychiatrist about the nature of the study and underwent clinical neurological assessment performed by a neurologist trained in movement disorders. Patients treated with anticholinergic drugs (orphenadrine, biperidene) were examined by the neurologist after a wash-out period lasting at least 3 days, after which the treatment could be restored.

We selected patients receiving pharmacological treatment with one or more AP drugs for at least 6 months and older than 40 years old. From a baseline cohort of 448 patients with schizophrenia, we diagnosed parkinsonism in 149 patients according to presence of two out of three cardinal parkinsonian signs (rest tremor, rigidity, bradykinesia) [2,4]. Among the remaining 299 patients who did not satisfy the criteria for parkinsonism diagnosis, we identified a group of patients who manifested two out of three axial parkinsonian signs (abnormality of trunk posture, hypomimia and short-step gait). Accordingly, we obtained two sub-groups of patients with schizophrenia, with and without parkinsonian axial signs (*Schiz-Axial*, *Schiz-NO-Axial*) which were the focus of this post-hoc analysis.

Socio-demographic and clinical data including age, sex, onset of schizophrenic symptoms, medical and family history of psychiatric or neurological diseases, and a detailed history of pharmacological treatment - including type, dosage and duration of current antipsychotic treatment and other psychotropic drugs (benzodiazepines, antiepileptic drugs, tricyclic antidepressants) - were obtained. Motor disability was evaluated by means of the motor section of the Unified Parkinson's Disease Rating Scale (UPDRS)

motor score (part III), which represents the most widely used instrument for measuring severity of parkinsonian symptoms and have excellent inter-rater and test-retest reliability. A difference ≥ 4 points in items 20–26 of the UPDRS III between the more and less affected sides was considered indicative of clinical asymmetry. The axial-UPDRS and limb-UPDRS motor scores were respectively calculated as sum of items 19, 27–29 and items 20–26 of motor UPDRS. Patients were included after giving written, informed consent to participate. Approval for the study was obtained at all local Ethics Committee of the participating centers.

Categorical data were analysed by chi-square statistics. Mann-Whitney two-sample statistics were used to analyse continuous data which were not normally distributed.

AP doses prescribed at discharge were converted into multiples of the defined daily dose (DDD) for each drug by dividing the prescribed daily dose (PDD) by the DDD [PDD/DDD]. The DDD is a theoretical unit of measurement of drug usage approved by the World Health Organisation for drug use studies. Expression of drug use in terms of multiples of DDDs makes it possible to calculate a cumulative measure of drug consumption for each patient, taking into account the concurrent use of more than one agent. A PDD/DDD ratio of one indicates that the dose prescribed is equal to the DDD of that drug; similarly to our previous studies, a ratio greater than two was defined as a high AP dose and was entered in the analysis. Significance level was set at $p \leq 0.05$.

3. Results

Out of 299 patients without parkinsonism originally enrolled in our cross-sectional analysis, 26 patients (8.7%) met the study criteria to be defined *Schiz-Axial* and were compared with 273 patients *Schiz-NO-Axial*. The Table 1 shows group comparisons for all socio-demographic and clinical variables. *Schiz-Axial* patients were significantly older and had longer disease duration compared to *Schiz-NO-Axial*. The two groups of patients did not differ for gender distribution, duration of AP treatment, frequency of family history for parkinsonism. Moreover, distribution of patients currently treated with two or more AP drugs was similar, as those treated with a high AP dose and with depot AP. Interestingly, *Schiz-Axial* patients were less likely to have been treated with two or more AP in the past compared to *Schiz-NO-Axial*. Finally, total UPDRS motor score as well as limb and axial UPDRS sub-scores were significantly increased in *Schiz-Axial* patients compared to *Schiz-NO-Axial* (Fig. 1).

4. Discussion

The present study showed that parkinsonian axial signs occur in those patients with schizophrenia who are older and have longer disease duration. No other clinical variable was different compared to patients without parkinsonian axial signs, including duration of exposure and current treatment with AP drugs, either in terms of number of AP prescribed or as overall cumulative dose.


Previously, we have demonstrated that parkinsonism in schizophrenia was related to older age and use of long-acting AP [2,5]. In the present study, older age and longer disease duration were related to development of axial parkinsonian signs in a cohort of schizophrenic patients without evidence of clear limb bradykinesia. Nevertheless, they had some degree of motor impairment, as pointed out by higher UPDRS motor scores. These data support the hypothesis that parkinsonism occurring over the clinical course of

Table 1

Distribution of demographic and clinical characteristics of patients with schizophrenia with and without parkinsonian axial signs.

	No-Axial (N = 273)	Axial (N = 26)	
Sex (males/females)	133/140	12/14	$p = 0.83$
Age (years)	52.9 ± 9.9	59.8 ± 12.8	*$p = 0.007$
Disease Duration (years)	22.4 ± 12.7	28.8 ± 14.6	*$p = 0.04$
Familial history for parkinsonism (Yes/No)	4/269	2/24	$p = 0.09$
AP duration (years)	22.4 ± 12.5	23.4 ± 17.09	$p = 0.9$
AP drugs in the past (<2/≥2)	124/149	19/7	*$p = 0.008$
Number of AP drugs at study entry (<2/≥2)	210/63	18/8	$p = 0.52$
AP dose (standard/high)	223/50	22/4	$p > 0.99$
Long-acting AP (Yes/No)	30/243	5/21	$p = 0.2$

AP = antipsychotic drugs.

Values in bold indicate significant differences ($p < 0.05$).**Fig. 1.** Motor disability evaluated by means of the Unified Parkinson's disease rating scale (UPDRS) was increased in patients with Schizophrenia and parkinsonian axial signs (Schiz-Axial) compared to those without (Schiz-NO-Axial). The figure shows total UPDRS motor score as well as limb and axial-subscores.

schizophrenia represents a heterogeneous condition not totally explained by post-synaptic blockage of D2-receptors by chronic antipsychotic treatment. Indeed, we could not demonstrate any difference in AP past and actual use as well as in their cumulative dose; interestingly, patients with axial parkinsonian signs were less likely to have been treated with less than two AP drugs. Hence, other mechanisms might explain occurrence of parkinsonian signs in schizophrenia [6]: 1) a direct neurotoxic effect of long term antipsychotic treatment [7]; 2) the development of concomitant idiopathic Parkinson's disease (PD), as suggested by an autopsy study which revealed the neuropathology features of PD in two out of seven patients who recovered from parkinsonism after stopping AP drugs [3]; 3) the natural history of schizophrenia manifesting with parkinsonian signs late over disease course [8]. The latter hypothesis might be suggested by our data demonstrating

association between axial parkinsonian signs is associated to longer disease course and older age. At this regard, we might speculate that parkinsonism might represent the motor side of schizophrenia, manifesting in the late phase of disease course. The vulnerability of older schizophrenic patients to parkinsonian signs in our cohort might reflect the age-related decline of the compensatory mechanisms aimed at maintaining normal dopaminergic neurotransmission [9]. Few studies have proposed the idea that parkinsonism not related to drug exposure may be part of the clinical spectrum of schizophrenia; indeed, parkinsonian signs have been demonstrated in patients naïve to neuroleptic drugs [8,10] and development of drug-induced parkinsonism has been predicted by older age and pre-treatment occurrence of motor signs (rigidity, bradykinesia, tremor) [11]. Moreover, schizophrenic patients naïve to AP presented hyperechogenicity of Substantia

Nigra which was linearly correlated with contralateral parkinsonism [10], as reported in patients with PD and in patients with schizophrenia treated with antipsychotic medications [12]. Unfortunately, in the current study we were unable to verify if patients with parkinsonian axial signs disclose denervation of nigro-striatal pathway, as we have previously done by ^{123}I -FP-CIT SPECT in the group with schizophrenia who satisfied diagnosis of parkinsonism [2]. Nevertheless, our findings are expected to stimulate future studies aiming to describe clinically and instrumentally schizophrenic patients who developed parkinsonian axial signs but not fully satisfying the diagnosis of parkinsonism according to current diagnostic criteria.

In conclusion, we propose that parkinsonism might represent a late motor feature of schizophrenia, associated to older age, longer disease duration and chronic exposure to antipsychotic drugs.

Authors' disclosures

Dr Francesca Morgante has received honoraria as a Consultant & Advisory Boards from Medtronic and Chiesi. She has received honoraria for speaking from UCB Pharma, Medtronic, Lundbeck, Chiesi, Abbvie. She serves in the Editorial board of Movement Disorders Clinical Practice and Frontiers in Movement Disorders.

Dr. Michele Tinazzi and Corrado Barbui have nothing to disclose.

The components of the Italian DIP study groups do not have anything to disclose.

Authors' contribution

Francesca Morgante: study concept and design, analysis and interpretation of data, draft and critical revision of the article for important intellectual content, final approval of the version to be submitted.

Michele Tinazzi and Corrado Barbui: study concept and design, interpretation of data, critical revision of the article for important intellectual content, final approval of the version to be submitted.

Italian DIP study group: acquisition of data, critical revision of the article for important intellectual content, final approval of the version to be submitted.

Acknowledgements

This study did not receive any funding.

References

- [1] M. Tinazzi, F. Morgante, A. Matinella, T. Bovi, A. Cannas, P. Solla, F. Marrosu, A. Nicoletti, M. Zappia, A. Luca, A. Di Stefano, L. Morgante, C. Pacchetti, B. Minafra, M. Sciarretta, C. Dallochio, S. Rossi, M. Olivelli, R. Ceravolo, D. Frosini, A. Cipriani, C. Barbui, Imaging of the dopamine transporter predicts pattern of disease progression and response to levodopa in patients with schizophrenia and parkinsonism: a 2-year follow-up multicenter study, *Schizophr. Res.* 152 (2–3) (2014) 344–349.
- [2] M. Tinazzi, A. Cipriani, A. Matinella, A. Cannas, P. Solla, A. Nicoletti, M. Zappia, L. Morgante, F. Morgante, C. Pacchetti, M. Sciarretta, C. Dallochio, S. Rossi, M. Malentacchi, R. Ceravolo, D. Frosini, S. Sestini, T. Bovi, C. Barbui, [(1)(2)(3)] FP-CIT single photon emission computed tomography findings in drug-induced Parkinsonism, *Schizophr. Res.* 139 (1–3) (2012) 40–45.
- [3] U.A. Shuaib, A.H. Rajput, C.A. Robinson, A. Rajput, Neuroleptic-induced Parkinsonism: clinicopathological study, *Mov. Disord.* 31 (3) (2016) 360–365.
- [4] M. Lorberboym, T.A. Treves, E. Melamed, Y. Lampi, M. Hellmann, R. Djaldetti, [123I]-FP/CIT SPECT imaging for distinguishing drug-induced parkinsonism from Parkinson's disease, *Mov. Disord.* 21 (4) (2006) 510–514.
- [5] M. Tinazzi, S. Ottaviani, I.U. Isaia, I. Pasquin, M. Steinmayr, C. Vampini, M. Pilleri, G. Moretto, A. Fiaschi, N. Smania, P. Giorgetti, A. Antonini, [123I]FP-CIT SPET imaging in drug-induced Parkinsonism, *Mov. Disord.* 23 (13) (2008) 1825–1829.
- [6] R. Erro, K.P. Bhatia, M. Tinazzi, Parkinsonism following neuroleptic exposure: a double-hit hypothesis? *Mov. Disord.* 30 (6) (2015) 780–785.
- [7] J. Park, S. Chung, H. An, J. Kim, J. Seo, D.H. Kim, S.Y. Yoon, Haloperidol and clozapine block formation of autophagolysosomes in rat primary neurons, *Neuroscience* 209 (2012) 64–73.
- [8] M.P. Caligiuri, J.B. Lohr, D.V. Jeste, Parkinsonism in neuroleptic-naive schizophrenic patients, *Am. J. Psychiatry* 150 (9) (1993) 1343–1348.
- [9] R. Fuente-Fernandez, M. Schulzer, L. Kuramoto, J. Cragg, N. Ramachandran, W.L. Au, E. Mak, J. McKenzie, S. McCormick, V. Sossi, T.J. Ruth, C.S. Lee, D.B. Calne, A.J. Stoessl, Age-specific progression of nigrostriatal dysfunction in Parkinson's disease, *Ann. Neurol.* 69 (5) (2011) 803–810.
- [10] D. Kamis, L. Stratton, M. Calvo, E. Padilla, N. Florenzano, G. Guerrero, R.B. Molina, J. Molina, G.A. de Erausquin, Sex and laterality differences in parkinsonian impairment and transcranial ultrasound in never-treated schizophrenics and their first degree relatives in an Andean population, *Schizophr. Res.* 164 (1–3) (2015) 250–255.
- [11] M.P. Caligiuri, J.B. Lohr, Instrumental motor predictors of neuroleptic-induced parkinsonism in newly medicated schizophrenia patients, *J.Neuropsychiatry Clin.Neurosci* 9 (4) (1997) 562–567.
- [12] D. Berg, B. Jabs, U. Mersdorf, H. Beckmann, G. Becker, Echogenicity of substantia nigra determined by transcranial ultrasound correlates with severity of parkinsonian symptoms induced by neuroleptic therapy, *Biol. Psychiatry* 50 (6) (2001) 463–467.